The following is from the CTA section 4 - "4.1 Company agrees that Institution and/or Principal Investigator shall have the first right to publish the results of the Study; provided, however, that none of the following actions shall be considered to be a publication of the results of the Study in violation of the publication rights of the Institution and/ or the Principal Investigator: (i) issuance of a press release disclosing the results of the Study (ii) the disclosure of results of the Study to investors, prospective investors of potential corporate partners or (iii) the disclosure of the results of the study to the Securities and Exchange Commission or any other regulatory authority or in any filing with therewith. Institution and/or Principal Investigator shall be free to publish the results of the Study." Re-read and note where it says "however, that none of the following actions shall be considered to be publication" _ Please note this section precedes my previous post here discussing the CTA stronger language in section 4 - that's the way it is written - all the legal mum-bo-jumbo
In plain language SYN will release news on the findings as they are not in any violation of the CTA because it is not classified as an official journal type publication. After reading my bookmarked CTA sections the past two days maybe not one of you will think I'm understanding this clearly. BUt I'm open to discuss this
A thought on this - Trying to read the fact (s) is not an easy task - in Liz's CTA stronger language quote I looked up the word constitute as defined "to set up or establish according to law or provision" - so I'll plug into that key phrase - "It is agreed by UCLA (Institution) that, without limitation, publication of an article substantially containing the information in the draft article provided to SYN(Company) by UCLA (Institution) Dr.V. (counsel) on or about June 30, 2015 shall set up or establish according to law or provision(constitute) such publication of Study results." _ This phrase is the section of the agreement "pursuant to Article 4 below. Is it not one in the same, Article 4? The word shall is key, imo - does this help?
In an important way this is comforting _ what will confirm my comfort level will be a little gift called fast-track status - because on the other side of the coin most of us(?) know the ties between the FDA, the big pharma companies, and politics / politicians - meaning, and especially from an FDA perspective, there is more money going around through ongoing treatment protocols etc _ But I'd think this case is different as a hospital origin medical condition and national interest that becomes a concern of the CDC - all this "should" make SYN 004 worthy for all involved and that includes the investor too, though maybe of a lesser importance
"learn and move on" - does it become any easier ? _ Often a bio like ours will pop way-way up a long-long time before sales / revenues - Then 2 or 3 years goes by before it hits near that high again _ To your point on selling too early - with the calendar activity we have most likely I would not choose to sell all my shares in one clip _ leverage is a worthy consideration, imo
those 3 times the .35 cent low was hit this year it never closed that day at .35 always a little higher - seems like it would be rather difficult to have a close below .35 - still I thinks it happens unless we get some good news 1st - high probability markets will correct / pull-back this year, imo
Thnx - and - if our SYN was a 35 $$ stock I'd be holding a $327,500 profit - patience - in '16 or '17
I just started looking into MCRB because I caught and article this a.m. titled "How a small drug maker enters market to soaring stock prices". It started sounding like SYN and our microbiome stuff with emphasis on c-diff.
Suggest checking out their site - go through yahoo finance to MCRB "profile" then home-page link - you know I'm long SYN and have been on this board for a year and a half - I'm not worried or concerned for now anyway it's just important to look into this kind of thing as a person trying to make some bucks this way / investing
usually if things are in the works and if possible they like to announce the goodies prior to - just maybe we'll get something within the next 10 days anyways
When was the IPO ? in '06 ? _ yahoo chart "max" time frame has Jan 8, '07 high $27. close $21. _ then on April 25, '07 a 1 for 3 reverse stock-split _ that chart "should" reflect prices adjusted for that split _ if it didn't then the 27 bucks becomes 9 - I don't know which it is _ it would be interesting to know the price the ipo went in at and how it traded high,low, & close that 1st day - you guys are talk'n 52 wk hi
along those lines recall DR say'n sometime back on at-least 2 occasions about take'n it private _ he probably had / has more than 1 reason for say'n so, but you've mentioned a couple of 'em anyways - I don't know how much rb4 changes that though for sure if the thought still exists in the back of his mind re going private or sell'n, that's pushed out a minimum of what 13 months? for going private - selling with revenues up like between 2/'16 to 6/'16 is a possible shot??
potential partners may bring an offer when data is available or even most likely will, but why do you think syn stated they will do an independent analysis of the data?
A little follow-up -
From June 29th SYN 010 IBS - In the 2nd half of '15 the reporting on topline results of phase 2 and initiating 2nd phase 2 trial.
From June 12th SYN 004 C-difficile - "We remain on track to complete and report preliminary data from 1st phase 2a clinical trial within the month and to initiate phase 2b(proof of concept) in the 3rd Q '15 _ Nothing new said just referenced
SYN's independent analysis will be what potential partners will move on to a deal or not _ That will be the outcome timeline for investors regards this stage of Trimesta, imo
The following key PR statement on Trimesta has been discussed here before, as you know - anyways - From the June 16th '15 Form 8 - K:
"Strategic partnering efforts supported by demonstrated therapeutic potential and safety profile of oral estriol are ongoing for the Company's relapsing-remitting multiple sclerosis program. The Company has been informed by UCLA that MRI analyses are ongoing to evaluate changes in the brain that correlate with improvements seen in clinical outcomes, and the Company now expects to report topline data 30 days following its receipt from UCLA." _ So this statement of fact is without a timeline since it says the UCLA MRI analyses are ongoing, which leaves the reporting date open. _ When SYN followed-up here with their 30 days following note I'll take that to mean "within" 30 days and no more than 30 days after, but SYN uses the phrase "expects to report" of which I'll take that as a slime to no chance it goes past 30 days _ They throw that in there in case one of life's unexpected things occurs, imo
price was at .50 and above 7 times ytd - that's .50 to .52 on 3/12, 16, 17, 19, 20, 23, & 24th with the high of .52 the 19th of Mar.- the 52 wk low of .35 was hit Feb 20th, Mar 26th & 31st - so 3 times ytd - Overall 7 months and counting - that's a lot and long time price consolidation
This is so key towards the end steps for the efficacy of the ligand - TGIF over n out
Sentiment: Strong Buy
Also if you haven't come across an article on this I think you'll enjoy it too - To better understand the connections between the lymphatic system and the brain, a team led by Drs. Antoine Louveau and Jonathan Kipnis of the University of Virginia School of Medicine used high-powered microscopes to examine the brains of mice. Their research was funded in part by NIH’s National Institute on Aging (NIA) and National Institute of Neurological Disorders and Stroke (NINDS). Findings appeared online on June 1, 2015, in Nature.
The scientists examined layers of tissue, known as meninges, that cover the brain and contain blood vessels and cerebrospinal fluid. While searching for structures associated with the meninges, the researchers noticed vessel-like patterns. These vessels contained markers of the lymphatic system. By injecting dye into anesthetized mice and tracking its path, they found that the vessels carried fluid and immune cells from the cerebrospinal fluid, along veins in the sinuses, and into nearby deep cervical lymph nodes. The researchers surmise that these vessels may serve as a second step in the drainage of fluid from the brain, after it’s drained into the cerebrospinal fluid through the glymphatic system.
These vessels may have gone undiscovered until now due to their hidden location. The method the team used to prepare the meninges kept these layers intact. The researchers found similar structures in autopsy specimens of human meninges. Organization of the vessels in the human central nervous system will now need to be determined.
The discovery of a pathway for immune cells to exit the central nervous system raises the question of whether disruption of this route may be involved in neurological disorders that are associated with immune system dysfunction, such as multiple sclerosis, meningitis, and Alzheimer’s disease.
“We think these vessels may play a role in pathogenesis of neurological conditions that have an immune component,” Kipnis says.
1st thnx - Can't wait for this new data to see more on estriol / trimesta and if there is any mention on the new mapping / finding of lymph vessels etc IL2 receptor relationship to estriol effects on t-cell expansion - like to see her mention of the compounds miconazole and clobetasol too
I hear you _ each to their own way of putting it all together _ I respect that and your choices _ I use to bat a tennis ball around with a guy who made enough to stop work'n in his early 40s - set-up his own portfolio of blue chip type stocks where he bought them only when at 52 week low or lower over time and living off the dividends _ He averages about 4.5% and never cares what the market is doing or where the stock price is only on rare occasions _ My preference is to spend more time learning, traveling, and sharing with well intended peoples - Best of Make'n $$s